Archive for the ‘psoriatic arthritis’ Category
The Last Plaque short film is now live
The new and stylish short film, “The Last Plaque,” sponsored by the nonprofit Psoriasis Cure Now (that’s us!), debuted on World Psoriasis Day, October 29, 2021. The film asks: “What happens when the world is finally free from plaque psoriasis?” We would also ask: “What would the end of psoriasis Continue Reading…
COVID-19, vaccination, and psoriasis: the latest in what you need to know
Despite our best hopes, COVID is still with us, and now vaccination news and debates confront us wherever we turn, from the internet to the local convenience store. For people with psoriasis and/or psoriatic arthritis, it raises many questions, as we try to balance potential risks from the coronavirus with Continue Reading…
COVID vaccine hesitancy in psoriasis patients not necessary, experts say
A study reviewed social media posts of psoriasis and/or psoriatic arthritis patients in the US and four European countries to learn the top reasons for COVID vaccine hesitancy among those who are hesitant and using biologics to treat their psoriatic disease. The most commonly cited concerns, it turns out, have Continue Reading…
Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials
Gilead Sciences and Galapagos jointly announced results from Phase Two (mid-stage) clinical trials for their JAK1 inhibitor filgotinib for psoriatic arthritis. The companies are jointly developing the investigational treatment. JAK inhibitors, taken as pills, are receiving much attention for their ability to help people with rheumatoid arthritis (RA), psoriatic arthritis, Continue Reading…
Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis
Eli Lilly and Company shared new data from its 52-week, head-to-head biologic clinical trial pitting its Taltz (ixekizumab) against AbbVie’s longtime blockbuster Humira (adalimumab) in patients with psoriatic arthritis who had not yet tried a biologic. Here’s the bottom line for those of you who just want the answers without Continue Reading…
Tremfya approval in U.S. for psoriatic arthritis looks likely
Tremfya (guselkumab), is approved by the U.S. Food and Drug Administration (FDA) and regulators elsewhere for the treatment of adults with moderate to severe plaque psoriasis. It is an IL-23 inhibitor that is very successful at improving skin psoriasis. It was approved in Europe in 2019 for active psoriatic arthritis, Continue Reading…
Company behind Humira and Skyrizi asks regulators to green-light Rinvoq for psoriatic arthritis
AbbVie, the North Chicago company behind the longtime blockbuster biologic Humira (adalimumab) and the new biologic Skyrizi (risankizumab-rzaa), has asked the U.S. Food and Drug Administration (FDA) and its European counterpart to approve its rheumatoid arthritis (RA) drug Rinvoq (upadacitinib) for psoriatic arthritis. Rinvoq is a JAK inhibitor administered as Continue Reading…
Our new “Psoriasis Journey” campaign is rolling out
Our new Psoriasis Journey campaign is rolling out now to prep for for an official June 8, 2020 launch. On that date, our volunteer patient with severe psoriasis is going to begin one of the cutting-edge psoriasis treatments we’ve been hearing so much about. You can follow along with his Continue Reading…
Cosentyx goes head to head against Humira in psoriatic arthritis…it’s mostly a draw
Two biologics that work on psoriatic disease differently – Cosentyx (drug name secukinumab, an IL-17a inhibitor) and Humira (drug name adalimumab, a TNF-alpha inhibitor) – were recently tested in a study designed and funded by Novartis, the company behind Cosentyx. The study pitted Cosentyx against Humira for 52 weeks in Continue Reading…
New patient registry PsoProtect for those battling both psoriasis and COVID-19/coronavirus could help provide treatment insights to both ailments
Scientists and physicians in the UK, working with an international coalition of experts and organizations, have launched a web-based registry that will gather health information on people with psoriasis who develop confirmed or suspected COVID-19/coronavirus. The results, if enough doctors participate, could provide important information in the treatment of both Continue Reading…
